Back to Browse Journals » International Journal of Nanomedicine » Volume 7

Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy

Authors Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, Gulino A

Published Date July 2012 Volume 2012:7 Pages 3637—3657

DOI http://dx.doi.org/10.2147/IJN.S23696

Received 9 January 2012, Accepted 28 February 2012, Published 20 July 2012

Evelina Miele,1,* Gian Paolo Spinelli,2,* Ermanno Miele,3 Enzo Di Fabrizio,3,6 Elisabetta Ferretti,4 Silverio Tomao,2 Alberto Gulino,1,5

1Department of Molecular Medicine, 2Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 3Nanostructures, Istituto Italiano di Tecnologia, via Morego, 30, 16163 Genova, 4Department of Experimental Medicine, Sapienza University of Rome, Rome, 5Center for Life Nanoscience, Istituto Italiano di Tecnologia, Rome, Italy, 6BIONEM lab, University of Magna Graecia, Campus S. Venuta, Viale Europa 88100 Catanzaro, Italy

*These authors contributed equally to this work

Abstract: During recent decades there have been remarkable advances and profound changes in cancer therapy. Many therapeutic strategies learned at the bench, including monoclonal antibodies and small molecule inhibitors, have been used at the bedside, leading to important successes. One of the most important advances in biology has been the discovery that small interfering RNA (siRNA) is able to regulate the expression of genes, by a phenomenon known as RNA interference (RNAi). RNAi is one of the most rapidly growing fields of research in biology and therapeutics. Much research effort has gone into the application of this new discovery in the treatment of various diseases, including cancer. However, even though these molecules may have potential and strong utility, some limitations make their clinical application difficult, including delivery problems, side effects due to off-target actions, disturbance of physiological functions of the cellular machinery involved in gene silencing, and induction of the innate immune response. Many researchers have attempted to overcome these limitations and to improve the safety of potential RNAi-based therapeutics. Nanoparticles, which are nanostructured entities with tunable size, shape, and surface, as well as biological behavior, provide an ideal opportunity to modify current treatment regimens in a substantial way. These nanoparticles could be designed to surmount one or more of the barriers encountered by siRNA. Nanoparticle drug formulations afford the chance to improve drug bioavailability, exploiting superior tissue permeability, payload protection, and the “stealth” features of these entities. The main aims of this review are: to explain the siRNA mechanism with regard to potential applications in siRNA-based cancer therapy; to discuss the possible usefulness of nanoparticle-based delivery of certain molecules for overcoming present therapeutic limitations; to review the ongoing relevant clinical research with its pitfalls and promises; and to evaluate critically future perspectives and challenges in siRNA-based cancer therapy.

Keywords: small interfering RNA, nanoparticles, cancer therapy, delivery strategies, biological barriers, clinical trials

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Research progress on siRNA delivery with nonviral carriers

Gao Y, Liu XL, Li XR

International Journal of Nanomedicine 2011, 6:1017-1025

Published Date: 11 May 2011

Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes

Pang Z, Gao H, Chen J, Shen S, Zhang B, Ren J, Guo L, Qian Y, Jiang X, Mei H

International Journal of Nanomedicine 2012, 7:3421-3432

Published Date: 6 July 2012

Progress on RNAi-based molecular medicines

Chen J, Xie JP

International Journal of Nanomedicine 2012, 7:3971-3980

Published Date: 26 July 2012

Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer

Abedini F, Hosseinkhani H, Ismail M, Domb AJ, Omar AR, Chong PP, Hong PD, Yu DS, Farber IY

International Journal of Nanomedicine 2012, 7:4159-4168

Published Date: 31 July 2012

Nanotechnology-based approaches in anticancer research

Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA

International Journal of Nanomedicine 2012, 7:4391-4408

Published Date: 9 August 2012

Modification of palm kernel oil esters nanoemulsions with hydrocolloid gum for enhanced topical delivery of ibuprofen

Salim N, Basri M, Rahman MBA, Abdullah DK, Basri H

International Journal of Nanomedicine 2012, 7:4739-4747

Published Date: 7 September 2012

Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies

Monteiro LM, Lione VF, do Carmo FA, do Amaral LH, da Silva JH, Nasciutti LE, Rodrigues CR, Castro HC, de Sousa VP, Cabral LM

International Journal of Nanomedicine 2012, 7:5175-5182

Published Date: 28 September 2012

Enhanced oral absorption of 20(S)-protopanaxadiol by self-assembled liquid crystalline nanoparticles containing piperine: in vitro and in vivo studies

Jin X, Zhang ZH, Sun E, Tan XB, Li SL, Cheng XD, You M, Jia XB

International Journal of Nanomedicine 2013, 8:641-652

Published Date: 12 February 2013

The inhibitory effect of small interference RNA protein kinase C-alpha on the experimental proliferative vitreoretinopathy induced by dispase in mice

Gao Q, Wang W, Lan Y, Chen X, Yang W, Yuan Y, Tan J, Zong Y, Jiang Z

International Journal of Nanomedicine 2013, 8:1563-1572

Published Date: 19 April 2013